EA200970067A1 - Агонисты ep2 - Google Patents

Агонисты ep2

Info

Publication number
EA200970067A1
EA200970067A1 EA200970067A EA200970067A EA200970067A1 EA 200970067 A1 EA200970067 A1 EA 200970067A1 EA 200970067 A EA200970067 A EA 200970067A EA 200970067 A EA200970067 A EA 200970067A EA 200970067 A1 EA200970067 A1 EA 200970067A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agonists
compounds
methods
preparation
intraocular pressure
Prior art date
Application number
EA200970067A
Other languages
English (en)
Inventor
Ганеш Прасанна
Чарльз Флойд Босуорт
Дженнифер Анн Ла Фонтэн
Original Assignee
Пфайзер Продактс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Продактс Инк. filed Critical Пфайзер Продактс Инк.
Publication of EA200970067A1 publication Critical patent/EA200970067A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/04—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к агонистам ЕР2, способам их получения, фармацевтическим композициям, содержащим такие соединения, и способам применения указанных соединений и композиций для снижения внутриглазного давления и тем самым лечения глаукомы.
EA200970067A 2006-07-28 2007-07-16 Агонисты ep2 EA200970067A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US83390706P 2006-07-28 2006-07-28
US94192307P 2007-06-04 2007-06-04
PCT/IB2007/002044 WO2008015517A2 (en) 2006-07-28 2007-07-16 Ep2 agonists

Publications (1)

Publication Number Publication Date
EA200970067A1 true EA200970067A1 (ru) 2009-08-28

Family

ID=38896126

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970067A EA200970067A1 (ru) 2006-07-28 2007-07-16 Агонисты ep2

Country Status (26)

Country Link
US (2) US7622475B2 (ru)
EP (1) EP2059507B1 (ru)
JP (1) JP4583500B2 (ru)
KR (1) KR101088942B1 (ru)
AP (1) AP2009004754A0 (ru)
AR (1) AR062122A1 (ru)
AU (1) AU2007280130B2 (ru)
BR (1) BRPI0714683A2 (ru)
CA (1) CA2659184C (ru)
CL (1) CL2007002207A1 (ru)
CR (1) CR10554A (ru)
EA (1) EA200970067A1 (ru)
EC (1) ECSP099071A (ru)
GT (1) GT200700064A (ru)
HK (1) HK1133876A1 (ru)
IL (1) IL196355A0 (ru)
MA (1) MA30604B1 (ru)
MX (1) MX2009001062A (ru)
NO (1) NO20090738L (ru)
NZ (1) NZ573964A (ru)
PE (1) PE20080408A1 (ru)
RS (1) RS20090002A (ru)
TN (1) TN2009000028A1 (ru)
TW (1) TWI372757B (ru)
UY (1) UY30511A1 (ru)
WO (1) WO2008015517A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648097B2 (en) * 2008-03-12 2014-02-11 Ube Industries, Ltd. Pyridylaminoacetic acid compound
PL2415763T3 (pl) 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
AU2010293410A1 (en) * 2009-09-11 2012-05-03 Ube Industries, Ltd. Substituted carbonyl compounds
KR20120068902A (ko) * 2009-09-11 2012-06-27 우베 고산 가부시키가이샤 아닐린 화합물
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
CN102666490A (zh) * 2009-12-25 2012-09-12 宇部兴产株式会社 氨基吡啶化合物
RU2013111281A (ru) * 2010-08-17 2014-09-27 Аллерган, Инк. Агонисты ер2 или ер4 для лечения помутнения роговицы
EA026702B1 (ru) 2011-09-16 2017-05-31 Санофи Производные анилина, их получение и терапевтическое применение
WO2013109991A1 (en) * 2012-01-20 2013-07-25 Acucela Inc. Substituted heterocyclic compounds for disease treatment
CA2867527A1 (en) 2012-05-03 2013-11-07 Takeda Gmbh Novel ep2 receptor agonists
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
TW201527282A (zh) * 2013-03-28 2015-07-16 Ube Industries 取代聯芳基化合物
JP2017206445A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 呼吸器疾患の治療及び／又は予防のための医薬組成物
JP2017206443A (ja) * 2014-09-26 2017-11-24 宇部興産株式会社 置換ビアリール化合物及び他の医薬の組み合わせ
RU2749952C2 (ru) * 2015-07-01 2021-06-21 Сантэн Фармасьютикал Ко., Лтд. Депо-препарат, содержащий сложный эфир лимонной кислоты

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
UA59384C2 (ru) 1996-12-20 2003-09-15 Пфайзер, Інк. Предотвращение потери костной массы и ее восстановление с помощью агонистов простагландина
UA67754C2 (ru) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агонисты простагландина и их применение при лечении расстройств костной массы
EP1000619A3 (en) 1998-06-23 2002-07-24 Pfizer Products Inc. Method for treating glaucoma
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
US20020161026A1 (en) 2000-11-07 2002-10-31 Paralkar Vishwas M. Combination therapies for the stimulation of bone growth
NZ532209A (en) 2001-11-30 2007-05-31 Pfizer Prod Inc Controlled release microparticle pharmaceutical composition for the sustained release of an EP2 receptor selective agonist for treating bone injury or bone defect
CA2473984A1 (en) * 2002-01-31 2003-08-07 Pfizer Products Inc. Metabolites of (3-{[4-tert-butyl-benzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid
AU2004216898A1 (en) 2003-03-04 2004-09-16 Pfizer Products Inc. Use of EP2 selective receptor agonists in medical treatment
US20050203086A1 (en) 2004-03-04 2005-09-15 Pfizer Inc. Methods of treatment using an EP2 selective receptor agonist
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma

Also Published As

Publication number Publication date
AP2009004754A0 (en) 2009-02-28
UY30511A1 (es) 2008-02-29
HK1133876A1 (en) 2010-04-09
KR20090023507A (ko) 2009-03-04
MX2009001062A (es) 2009-02-06
EP2059507B1 (en) 2013-03-20
US7622475B2 (en) 2009-11-24
AU2007280130A1 (en) 2008-02-07
WO2008015517A3 (en) 2008-06-12
WO2008015517A2 (en) 2008-02-07
CL2007002207A1 (es) 2008-02-01
TN2009000028A1 (fr) 2010-08-19
US20100105905A1 (en) 2010-04-29
CR10554A (es) 2009-02-10
CA2659184A1 (en) 2008-02-07
NZ573964A (en) 2010-11-26
EP2059507A2 (en) 2009-05-20
PE20080408A1 (es) 2008-04-28
AU2007280130B2 (en) 2011-09-22
TW200817360A (en) 2008-04-16
MA30604B1 (fr) 2009-07-01
CA2659184C (en) 2012-02-21
RS20090002A (en) 2010-06-30
US20080045545A1 (en) 2008-02-21
IL196355A0 (en) 2009-09-22
GT200700064A (es) 2009-06-18
KR101088942B1 (ko) 2011-12-01
TWI372757B (en) 2012-09-21
BRPI0714683A2 (pt) 2013-03-26
AR062122A1 (es) 2008-10-15
JP2009544751A (ja) 2009-12-17
JP4583500B2 (ja) 2010-11-17
NO20090738L (no) 2009-04-27
ECSP099071A (es) 2009-02-27

Similar Documents

Publication Publication Date Title
EA200970067A1 (ru) Агонисты ep2
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
EA200970156A1 (ru) Пиридизиноновые производные
EA201071169A1 (ru) ГИДРОКСИМЕТИЛПИРРОЛИДИНЫ В КАЧЕСТВЕ АГОНИСТОВ АДРЕНЕРГИЧЕСКИХ РЕЦЕПТОРОВ β3
EA200970337A1 (ru) Ингибиторы котранспортера натрий-глюкозы 2 и способы их применения
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA201070247A1 (ru) Ингибиторы протеасом
EA201170772A1 (ru) Органические соединения
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
EA201170227A1 (ru) Имидазолкарбоксамиды
EA200970967A1 (ru) Оксадиазол замещенные производные индазола для применения в качестве агонистов сфингозин 1-фосфата (sip)
UY30573A1 (es) N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
ECSP088854A (es) Moduladores bencimidazolicos de vr1
EA201290416A1 (ru) Новые спиропиперидиновые соединения
EA201270590A1 (ru) Ингибиторы акт
EA200971140A1 (ru) Триарильные соединения и композиции, их содержащие
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
EA201000814A1 (ru) 5-[(3,3,3-трифтор-2-гидрокси-1-арилпропил)амино]-1h-хинолин-2-оны, способ их получения и их применение в качестве противовоспалительных средств
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств